acqua+
ONDA NITRICA
ndo sei finito???????????passa a salutare gli amicici della setta ILLUVIEN!
pochino, pochino ,,,, io accumulo
sempre in relax
pSivida Corp. (PSDV) ,,,,, un GIOIELLO !!!
- Creatore Discussione acqua+
- Data di Inizio
pochino, pochino ,,,, io accumulo
sempre in relax
acqua+
ONDA NITRICA
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ:PSDV - News)(ASX:PVA - News)(FF
V3), a drug delivery company with two of the only three ophthalmic sustained release delivery products approved by the FDA for treatment of back-of-the-eye diseases, today announced financial results for its first quarter ended September 30, 2009.
The Company reported a consolidated net loss of $1.6 million, or $0.09 per share for the quarter ended September 30, 2009, compared to a consolidated net loss of $471,000, or $0.03 per share, for the quarter ended September 30, 2008. Results for the three months ended September 30, 2009 included a $1.5 million non-cash expense for the change in fair value of derivatives associated with the Company’s outstanding warrants denominated in Australian dollars. This compared to non-cash income of $1.3 million for the change in fair value of derivatives for the quarter ended September 30, 2008.
Revenues, which were predominantly related to the Company’s amended collaboration agreement with Alimera Sciences, Inc. (Alimera), totaled $3.4 million for the three months ended September 30, 2009 compared to revenues of $2.8 million for the three months ended September 30, 2008. Cash and cash equivalents totaled $6.0 million at September 30, 2009.
“This is a very exciting time for the Company, with the 2-year top line safety and efficacy data from the ongoing Phase III Iluvien® trials for the treatment of diabetic macular edema (DME) expected by the end of December,” said Dr. Paul Ashton, President and CEO of pSivida. “DME is a potentially blinding eye disease that affects over one million people in the United States. Currently there are no FDA-approved drugs for the treatment of DME.”
“The Phase III Iluvien trials are being conducted by our partner Alimera,” said Dr. Ashton. “Assuming positive data, Alimera plans to file an NDA with the FDA in the second quarter of calendar 2010 and request Priority Review. Priority Review could result in a decision from the FDA by as early as the end of 2010 and, if positive, Alimera is planning first sales of Iluvien as early as Q1 of calendar 2011. Alimera is also engaged in investigator-sponsored studies designed to assess the safety and efficacy of Iluvien in wet and dry age-related macular degeneration and retinal vein occlusion.”
Dr. Ashton continued, “We have continued to manage our cash burn carefully, while we are advancing the development of our non-Iluvien drug delivery platforms, including our BioSilicon technology.”
“Commencing April 2010, the annual interest rate on our $15 million conditional note from Alimera increases to 20% and monthly principal payments of $500,000 are scheduled to begin. Payment of the conditional note accelerates on the occurrence of certain liquidity events for Alimera. FDA approval of Iluvien would trigger a $25 million milestone from Alimera and, once commercialized, pSivida is entitled to receive 20% of Iluvien profits,” stated Dr. Ashton.
pSivida Corp. Reports Results for the First Quarter Ended September 30, 2009 - Yahoo! Finance
V3), a drug delivery company with two of the only three ophthalmic sustained release delivery products approved by the FDA for treatment of back-of-the-eye diseases, today announced financial results for its first quarter ended September 30, 2009.The Company reported a consolidated net loss of $1.6 million, or $0.09 per share for the quarter ended September 30, 2009, compared to a consolidated net loss of $471,000, or $0.03 per share, for the quarter ended September 30, 2008. Results for the three months ended September 30, 2009 included a $1.5 million non-cash expense for the change in fair value of derivatives associated with the Company’s outstanding warrants denominated in Australian dollars. This compared to non-cash income of $1.3 million for the change in fair value of derivatives for the quarter ended September 30, 2008.
Revenues, which were predominantly related to the Company’s amended collaboration agreement with Alimera Sciences, Inc. (Alimera), totaled $3.4 million for the three months ended September 30, 2009 compared to revenues of $2.8 million for the three months ended September 30, 2008. Cash and cash equivalents totaled $6.0 million at September 30, 2009.
“This is a very exciting time for the Company, with the 2-year top line safety and efficacy data from the ongoing Phase III Iluvien® trials for the treatment of diabetic macular edema (DME) expected by the end of December,” said Dr. Paul Ashton, President and CEO of pSivida. “DME is a potentially blinding eye disease that affects over one million people in the United States. Currently there are no FDA-approved drugs for the treatment of DME.”
“The Phase III Iluvien trials are being conducted by our partner Alimera,” said Dr. Ashton. “Assuming positive data, Alimera plans to file an NDA with the FDA in the second quarter of calendar 2010 and request Priority Review. Priority Review could result in a decision from the FDA by as early as the end of 2010 and, if positive, Alimera is planning first sales of Iluvien as early as Q1 of calendar 2011. Alimera is also engaged in investigator-sponsored studies designed to assess the safety and efficacy of Iluvien in wet and dry age-related macular degeneration and retinal vein occlusion.”
Dr. Ashton continued, “We have continued to manage our cash burn carefully, while we are advancing the development of our non-Iluvien drug delivery platforms, including our BioSilicon technology.”
“Commencing April 2010, the annual interest rate on our $15 million conditional note from Alimera increases to 20% and monthly principal payments of $500,000 are scheduled to begin. Payment of the conditional note accelerates on the occurrence of certain liquidity events for Alimera. FDA approval of Iluvien would trigger a $25 million milestone from Alimera and, once commercialized, pSivida is entitled to receive 20% of Iluvien profits,” stated Dr. Ashton.
pSivida Corp. Reports Results for the First Quarter Ended September 30, 2009 - Yahoo! Finance
magolibero
..se la sà gira..
11/18/2009 10:17:45 AM Market Open
NASDAQ Last Sale
3.50 + 0.22 + 6.71%
NASDAQ Last Sale
3.50 + 0.22 + 6.71%
acqua+
ONDA NITRICA
DickSIM
Prima o poi....ci becco!
acqua+
ONDA NITRICA
nonostante in mercati in cac.ca ,,, il gioiellino avanza ,,,,,
,,, e ritornarono a vedere i 4
4,01
Similar threads
